Protonix competition has knock-on effect for Wyeth's second-quarter results
This article was originally published in Scrip
Wyeth's sales continued to grow in the second quarter to $5.9 billion, up by 5% from the same period last year, but failed to stop the company's net income from decreasing by 6% to $1.1 billlion. Without the positive effect of the weak dollar, sales would have grown just 1%. Pharmaceutical sales grew by 5% to $5 billion.